SCHEMBL3324203

SCHEMBL3324203

CCCCCCCCCN1C[C@H](O)[C@@H](O)[C@@H](O)[C@H]1CO

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GBA2 Q9HCG7 17/20 1.00
GBA1 P04062 8/20 1.00
GAA P10253 3/20 1.00
UGCG Q16739 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17189564 1.00 GBA2 (1.00) GBA2GBA1GAAUGCG
SCHEMBL3017802 1.00 GBA2 (1.00) GBA2GBA1GAAUGCG
SCHEMBL17243607 1.00 GBA2 (1.00) GBA2GBA1GAAUGCG
SCHEMBL13175020 1.00 GBA2 (1.00) GBA2GBA1GAAUGCG
SCHEMBL6821239 1.00 GBA2 (1.00) GBA2GBA1GAAUGCG
SCHEMBL13253278 1.00 GBA2 (1.00) GBA2GBA1GAAUGCG
SCHEMBL3020875 1.00 GBA2 (1.00) GBA2GBA1GAAUGCG
SCHEMBL2268575 1.00 GBA2 (1.00) GBA2GBA1GAAUGCG
SCHEMBL2789051 1.00 GBA2 (1.00) GBA2GBA1GAAUGCG
SCHEMBL9797495 1.00 GBA2 (1.00) GBA2GBA1GAAUGCG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1210082-B1 LONG CHAIN N-ALKYL COMPOUNDS AND OXA-DERIVATIVES THEREOF AND USE AS ANTIVIRAL COMPOSITIONS UNIV OXFORD (GB) 2008-01-02 EP claimed
JP-2003506406-A 2003-02-18 JP claimed
EP-1210082-A2 LONG CHAIN N-ALKYL COMPOUNDS AND OXA-DERIVATIVES THEREOF AND USE AS ANTIVIRAL COMPOSITIONS THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) 2002-06-05 EP claimed
WO-2001010429-A2 LONG CHAIN N-ALKYL COMPOUNDS AND OXA-DERIVATIVES THEREOF AND USE AS ANTIVIRAL COMPOSITIONS THE CHANCELLOR, MASTERS, AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) 2001-02-15 WO claimed
US-9089515-B2 Long chain N-alkyl compounds and oxa-derivatives thereof THOMAS JEFFERSON UNIVERSITY (US) 2015-07-28 US disclosed
US-7816560-B1 Long chain n-alkyl compounds and oxa-derivatives thereof THOMAS JEFFERSON UNIVERSITY (US) 2010-10-19 US disclosed
US-20100137365-A1 Long chain N-alkyl compounds and oxa-derivatives thereof THOMAS JEFFERSON UNIVERSITY 2010-06-03 US disclosed
EP-1210082-B1 LONG CHAIN N-ALKYL COMPOUNDS AND OXA-DERIVATIVES THEREOF AND USE AS ANTIVIRAL COMPOSITIONS UNIV OXFORD (GB) 2008-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137365-A1 Long chain N-alkyl compounds and oxa-derivatives thereof OXA1L, OTC, PAICS GBA2 2830/4885GBA1 2627/4885GAA 3365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.